Cycle on Jun 30, 2026

I will begin by listing the open threads and reading the notes associated with this topic to see what specific questions or watches are currently active and what findings have already been documented.

I will now read the existing notes to see what has been documented on these subjects and ensure I don't duplicate existing material, but rather extend and update it.

I see that there are several watches and existing notes. Let's do a general recent search to see what is happening in the science and public health space, focusing on major drug approvals, trial readouts, disease outbreaks, or policy shifts that have occurred within the last week or so, and specifically check on some of our active watches. Let's check the watches. 1. `Amgen Tavneos FDA hearing submission and public docket close` - This watch had a fire date of June 29, 2026. What happened with Amgen's Tavneos? The note `amgen-tavneos-eu-revocation-us-fda-extension` says: "On June 29, 2026, the global regulatory and scientific crisis surrounding Amgen's rare autoimmune drug Tavneos (avacopan) reached a dramatic turning point. The New England Journal of Medicine...". Let's search for Tavneos updates to see if there are any other recent updates. 2. `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA` - Let's see if there is any update. 3. `FDA Cellular, Tissue, and Gene Therapies Advisory Committee meeting scheduled for July 29, 2026, to discuss Capricor's BLA for deramiocel in DMD cardiomyopathy` - No, that's in July. 4. `FDA advisory committee meeting scheduled for late July 2026 to discuss Replimune's resubmitted BLA for RP1 in advanced melanoma` - That's in late July. 5. `GondolaBio's global Phase 2b/3 PATHWAY trial of PORT-77 in patients with EPP and XLP, targeted for Q3 2026` - Let's search if there has been any update. 6. Let's do a broad web search for the latest medical/science news from the last week (end of June 2026) to see what else has happened. Let's execute a web search with `sort="recent"` and `freshness="week"` to see what the newest major developments in health and science are. I will state my intent first. I will search for the latest health, medicine, and science news from the past week to find any major new regulatory decisions, clinical trial results, or public health emergencies.

I see some highly relevant recent articles: 1. `Sobi’s Gout CRL Is a Third-Party Manufacturing Indictment — And the Industry Wrote the Script` - June 26/30, 2026. Sobi received a CRL for "NASP" (or some other drug for gout) citing third-party manufacturing failures. Let's look into this! 2. `Definium’s Phase 3 LSD Win Is Real. The Fracture It Exposed Is Bigger.` - June 30, 2026. Definium's Phase 3 LSD trial win. 3. `Genmab’s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCL` - June 30, 2026. 4. `FDA Approves Roflumilast Cream for Plaque Psoriasis in Children Age 2+` - June 30, 2026. 5. `Medical journal retracts paper on Amgen’s Tavneos drug trial after FDA findings` - June 30, 2026. This is a crucial update to our Tavneos story! Let's fetch the details of these. Let's do a quick search on Sobi's CRL first to see what drug and what manufacturing failure occurred. Then we'll search for Definium's LSD win, and Genmab's Epcoritamab. I will search for Sobi's gout CRL to find the specific drug, the reason for the FDA's rejection, and other context.

Excellent! Sobi's NASP (nanoencapsulated sirolimus plus pegadricase) for uncontrolled gout received a CRL from the FDA on June 26, 2026. The issue is manufacturing-related. Let's fetch the Sobi press release or a news article to get the details. Let's look at `https://www.sobi.com/en/press-releases/sobi-receives-complete-response-letter-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465072` or the Clinical Trial Vanguard article `https://www.clinicaltrialvanguard.com/clinops-watchdog/sobis-gout-crl-is-a-third-party-manufacturing-indictment-and-the-industry-wrote-the-script/`. I'll fetch the Sobi press release first, and maybe the Clinical Trial Vanguard article as well. Let's do a search on Definium's Phase 3 LSD win to understand what that is. I will state my intent first. I will search for "Definium Phase 3 LSD" to find information on the drug, the trial results, and the indications.

Ah! Definium Therapeutics (formerly MindMed) announced positive Phase 3 results for DT120 ODT (a proprietary formulation of lysergide / LSD) in Major Depressive Disorder (MDD) from its "Emerge" study. Let's look up this study and get the exact details. Let's do a fetch of a couple of these sources. Let's also check on Genmab's Epcoritamab Phase 3 trial. I will state my intent first. I will search for "Genmab epcoritamab Phase 3 DLBCL" to see what specific trial met its goals and the data.

Let's search for "Genmab epcoritamab lenalidomide Phase 3 DLBCL" to get the latest press release, as the clinical trial vanguard article mentioned: `Genmab’s Epcoritamab Plus Lenalidomide Meets Phase 3 Goal in Relapsed DLBCL` Let's see if we can find this news. I will state my intent first. I will search for the specific news about Genmab's Epcoritamab plus lenalidomide meeting its Phase 3 goal in relapsed DLBCL.

Awesome! On June 29, 2026, Genmab / AbbVie announced positive Phase 3 results for Epcoritamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The trial is EPCORE DLBCL-2 (or another one, let's look at the press releases to confirm). Let's fetch the Genmab press release: `https://view.news.eu.nasdaq.com/view?id=be604a6149621fc2d902917bcf39eb23f&lang=en&src=micro` or `https://news.abbvie.com/2026-06-29-AbbVie-Announces-Positive-Phase-3-Results-for-Epcoritamab-Plus-Lenalidomide-in-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma`. First, let's fetch the Amgen Tavneos retract/EU revocation news as that is a major update to a prior finding. Our prior findings include: - `amgen-tavneos-fda-scrutiny-withdrawal-dispute` - `amgen-tavneos-eu-revocation-us-fda-extension` - `amgen-tavneos-chmp-revocation-data-integrity` Wait, `amgen-tavneos-eu-revocation-us-fda-extension` was updated on June 30, 2026. Let's read this note to see what it covers, so we can see if we need to update it or if it has already been updated. Let's use `web_fetch` or search to see what else we can find. Oh! Wait, we can't search notes with `web_fetch`, but we can read them. Wait, can we read the content of `amgen-tavneos-eu-revocation-us-fda-extension`? The `read_notes` returned previews of the notes, but let's see if we can read the full body of a note. Ah, wait, there is no tool to read a specific note's full body, but `read_notes` returns the preview. Wait, let's check if we can read it or if there is another way. Let's look at the tools. We have `read_notes` which lists the current set of notes, and returns slug, title, preview, updated_at, and source_count. It does not return the full body. But we can write a note to update it. Let's do a search on Tavneos to see the latest news and then update our Tavneos note if needed. Let's fetch: 1. `https://www.jpost.com/health-and-wellness/article-900899` or others about Tavneos and NEJM retraction. 2. `https://news.abbvie.com/2026-06-29-AbbVie-Announces-Positive-Phase-3-Results-for-Epcoritamab-Plus-Lenalidomide-in-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-Cell-Lymphoma` (or the Genmab one) 3. `https://definiumtx.com/pipeline/dt120/` or `https://www.statnews.com/2026/06/22/definium-lsd-dt120-major-depression-phase-3-data/` (or Fierce Biotech) 4. `https://www.sobi.com/en/press-releases/sobi-receives-complete-response-letter-fda-nasp-nanoencapsulated-sirolimus-plus-pegadricase-2465072` Let's do this sequentially. I will state my intent first. I will fetch the article about the NEJM retraction of the Tavneos clinical trial paper to gather the exact quotes and findings.

This is useful. Let's look at Sobi's CRL. Swedish Orphan Biovitrum AB (Sobi) received a Complete Response Letter (CRL) from the FDA on June 26, 2026, for its BLA for NASP (nanoencapsulated sirolimus plus pegadricase) for uncontrolled gout. The issue was chemistry, manufacturing, and controls (CMC) and contract manufacturing facility deficiencies, with no clinical safety or efficacy concerns identified. Let's see if there is an existing note on Sobi's gout drug. Looking at the list of notes, there isn't one specifically for Sobi's NASP. So we should create a new note with a fresh slug like `sobi-nasp-gout-fda-crl-manufacturing`. Let's fetch the Genmab press release or AbbVie press release for Epcoritamab plus lenalidomide in relapsed/refractory DLBCL. I will state my intent first. I will fetch the AbbVie press release on the Phase 3 results of Epcoritamab plus lenalidomide in relapsed/refractory DLBCL.

This is a major Phase 3 trial readout. - AbbVie/Genmab's subcutaneous CD3xCD20 bispecific antibody EPKINLY/TEPKINLY (epcoritamab) plus oral immunomodulatory drug Revlimid (lenalidomide) met its primary endpoint in the Phase 3 EPCORE DLBCL-4 trial (NCT06508658). - The trial evaluated this chemotherapy-free regimen against standard-of-care chemoimmunotherapy (R-GemOx) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who had received at least one prior line of therapy. - The combo reduced the risk of disease progression or death by 60% (US censoring rules, HR 0.40) or 56% (outside US, HR 0.44). - This is a highly significant victory and represents a chemotherapy-free option in the second-line setting. Let's check the watches on this. Is there a watch on Epcoritamab? Wait, there is a watch on: `Global Phase 3 trial readouts for ivonescimab (HARMONi studies)` But there isn't a watch on Epcoritamab in DLBCL. There is a watch on `sBLA submission for Zynlonta plus rituximab in r/r DLBCL` (which has LOTIS-5 trial safety concerns). This epcoritamab Phase 3 success is a direct competitor or relevant to the DLBCL space. We should write a new note for this. What slug should we use? Let's use `genmab-abbvie-epcoritamab-dlbcl-phase-3-success`. Wait, let's also check the FDA's new "Expedited-IND Pilot program" mentioned in the web search results. `Health officials launch clinical trial reforms to counter China threat` - "The Food and Drug Administration (FDA) on Monday [June 29, 2026] launched a new initiative to speed up early-stage clinical trials as part of an effort to reduce..." This is a direct follow-up/extension to `hhs-clinical-trials-reform-operation-trailblazer`! Let's search for "Expedited-IND Pilot program" or FDA's real-time clinical trials initiative or clinical trial reforms to counter China threat. Let's do a search on this. I will state my intent first. I will search for the FDA's newly launched clinical trial reform initiatives (including the Expedited-IND Pilot and Real-Time Clinical Trials) to see how they fit into "Operation Trailblazer".

Ah! The Federal Register notice `Expedited Investigational New Drug Pilot Program; Request for Information` was published on June 24, 2026. Let's fetch the Federal Register document or an article summarizing it, and also see how it ties into "Operation Trailblazer" (launched June 22, 2026, under HHS and RFK Jr.). Let's fetch: `https://www.federalregister.gov/documents/2026/06/24/2026-12621/expedited-investigational-new-drug-pilot-program-request-for-information` or search for articles about it. Let's first search about "Expedited Investigational New Drug Pilot Program" to get a concise summary. I will state my intent first. I will search for summaries of the FDA's "Expedited Investigational New Drug Pilot Program" proposed in late June 2026 to understand its goals, structure, and relation to Operation Trailblazer.

Let's fetch `https://www.raps.org/resource/hhs-and-fda-propose-clinical-trial-reforms-to-expedite-drug-development.html` or `https://www.arnoldporter.com/en/perspectives/advisories/2026/06/fda-proposes-expedited-investigational-new-drug-pilot-program` to understand the details of this "Expedited-IND Pilot program" and see how it fits into the "Operation Trailblazer" story. Let's do that now! I will state my intent first. I will fetch the Arnold & Porter article detailing the FDA's proposed Expedited Investigational New Drug (IND) Pilot Program to get a clear policy and legal breakdown of this major development.

This is a fantastic update to `hhs-clinical-trials-reform-operation-trailblazer`. Let's analyze this carefully. - Operation Trailblazer was formally launched on June 22, 2026, by HHS (led by RFK Jr.) and FDA. - On June 24, 2026, the FDA took a major step under this initiative by publishing a Request for Information (RFI) in the Federal Register proposing the **Expedited-IND Pilot Program**. - This pilot aims to reduce the start-up time for first-in-human (FIH) clinical trials (Phase 1) in the U.S. by 6 to 12 months, and cut overall clinical trial timelines in half. - The core of the proposal is the creation of a network of **"Qualified Research Institutions" (QRIs)**. QRIs would pre-screen IND components (pharmacology/toxicology, clinical, CMC) and make rolling recommendations to sponsors and the FDA. - This represents a regulatory effort to combat the shifting of early-stage (Phase 1) clinical trials to China, which took the lead in global Phase 1 share in 2021. - The FDA also clarified CMC expectations for Phase 1 INDs and issued a revised draft of its Substantial Evidence Guidance. - The public comment period for the RFI is open until **July 22, 2026**. Let's check the existing note `hhs-clinical-trials-reform-operation-trailblazer`. It was updated on June 30, 2026. Let's see if we should update it or if we can write a specific note on the "Expedited-IND Pilot Program" or if it is already covered. The preview of `hhs-clinical-trials-reform-operation-trailblazer` is: "On June 22, 2026, the U.S. Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., in coordination with the FDA, NIH, and other federal agencies, formally launched..." Wait, it's perfect to update `hhs-clinical-trials-reform-operation-trailblazer` to integrate this newly proposed Expedited-IND Pilot Program and the Federal Register RFI from June 24, 2026, as it is the key operational mechanism of Operation Trailblazer. Wait, let's also investigate the Tavneos update. The *New England Journal of Medicine* (NEJM) on June 29, 2026, retracted the pivotal 2021 clinical trial paper for Amgen's Tavneos (avacopan). This is a huge development! Let's see: - The retraction was requested by two academic authors of the study after an FDA investigation found that results for 9 patients were altered and some researchers were told who received the drug and who did not (unblinding). - Amgen says it respects the journal's decision and is preparing a "re-adjudication" of the trial's results by the Duke Clinical Research Institute (DCRI) to submit to the FDA by July 29, 2026. - This is a direct trigger of our watch: `Amgen Tavneos FDA hearing submission and public docket close` (fire date June 29, 2026). Wait, did the FDA extend the hearing submission deadline? Let's check. The article says: "results... will be shared with the FDA as part of our hearing submission due by July 29 and submitted for publication." So the deadline was extended to July 29, 2026! Let's check the note `amgen-tavneos-eu-revocation-us-fda-extension` to see if we should update it. It was updated on June 30, 2026, and its title is: `Amgen's Tavneos Faces EU Revocation over Data Integrity as U.S. FDA Hearing Deadline is Extended and NEJM Retracts Pivotal Trial`. Wait, if it was already updated on June 30, 2026, let's see if there are other details we should add or if it already covers the NEJM retraction. Let's read the preview of `amgen-tavneos-eu-revocation-us-fda-extension`: "On June 29, 2026, the global regulatory and scientific crisis surrounding Amgen's rare autoimmune drug Tavneos (avacopan) reached a dramatic turning point. The New England Journal of Medicine..." So it seems this note *already* covers the NEJM retraction and the extension of the FDA hearing deadline. Wait, let's double check if there are other watches that have fired. What about the watch `Amgen Tavneos FDA hearing submission and public docket close`? Let's see: the description is "Monitor Amgen's submission of the Duke Clinical Research Institute (DCRI) independent re-evaluation of the ADVOCATE trial data and the close of the FDA public comment period on the proposed withdrawal of Tavneos." And the trigger says "Fires when Amgen submits its evidence and the public docket closes on June 29, 2026." But the article says the submission is now due by **July 29, 2026** because of the extension. So this watch has *not* fully resolved yet, but its deadline has been extended to July 29, 2026. Wait! We could record an event on this watch to note the extension of the deadline to July 29, 2026, and update the watch, or keep it open. Since the watch is `one_shot` with a fire date of June 29, 2026, but the actual submission was extended to July 29, we should record an event noting that the deadline was extended and set `resolves: false` to keep it open, or we can update the watch. Wait, we cannot directly update the watch's fire date through `record_watch` unless we register a new one, but we can call `record_event` with `resolves: false` to keep it active and explain the new date, or we can register a new watch. Let's record the event on the thread `019ec855-5381-7936-a3b6-a40d207e679d`. Let's search for "Definium LSD" to find more details about its Phase 3 Emerge trial results. I will state my intent first. I will search for the specific details of Definium's Phase 3 Emerge trial of DT120 in major depressive disorder (MDD) to get the exact data points and quotes.

Let's fetch the Definium press release or a detailed article to get the exact data. Let's fetch: `https://ir.definiumtx.com/news-events/press-releases/detail/232/definium-therapeutics-announces-positive-topline-results-from-phase-3-emerge-study-of-dt120-orally-disintegrating-tablet-odt-in-major-depressive-disorder` or `https://www.fiercebiotech.com/biotech/definiums-lsd-formula-produces-best-data-ever-seen-pivotal-depression-trial-ceo-says`. Let's fetch the FierceBiotech article as it will have both the company's perspective and some independent analysis. I will fetch the FierceBiotech article on Definium's Phase 3 LSD trial in major depressive disorder to gather key data points and quotes.

This is an incredibly rich and exciting story. Let's analyze it: - Definium Therapeutics (formerly MindMed, which rebranded in January 2026) released topline Phase 3 data from its 149-patient **Emerge trial** (NCT06941844) evaluating **DT120 ODT** (orally disintegrating tablet), a proprietary formulation of lysergide (LSD), in Major Depressive Disorder (MDD) on June 22, 2026. - The trial met all primary and key secondary endpoints. - At 6 weeks (the primary endpoint), patients who received a single 100µg dose of DT120 ODT experienced an **8.1-point placebo-adjusted reduction** in symptom severity on the Montgomery-Åsberg Depression Rating Scale (MADRS) (p-value was highly significant). - At 12 weeks (secondary endpoint), the placebo-adjusted MADRS reduction was **7.1 points**, showing strong durability. - Definium CEO Robert Barrow claimed this represents "the best data ever seen in a pivotal study of depression," showing a magnitude, rapidity, and durability unmatched by competitors. For comparison, J&J's Spravato saw a 6.8-point reduction in its trial, and existing oral drugs like Trintellix and Auvelity show lower reductions. - Safety: No new safety signals, and no signs of increased suicidal ideation or behavior. Patients are monitored by an attendant for an 8-hour session, providing a "grounding force" but no active psychological intervention (unlike some competitors such as Compass Pathways). - Political backdrop/context: The psychedelic space is under intense spotlight following an executive order signed by President Trump in April 2026 instructing the FDA to grant priority review vouchers to companies working in the space (such as Compass, Usona Institute, and Transcend Therapeutics). Definium was not granted a voucher. Interestingly, Definium's Chief Medical Officer Daniel Karlin explicitly stated they want to avoid "an approval that has a political flavor to it" or any shortcuts that seem unscientific, especially given the controversy over political influence at the FDA. - This is a major breakthrough in psychedelic medicine, and we should write a dedicated finding for it under the slug `definium-dt120-lsd-depression-phase-3-success`. Wait, let's also search for any other recent updates. Let's check the watch: `Amgen Tavneos FDA hearing submission and public docket close` Wait! The public docket close was June 29, 2026, but the hearing submission has been extended to July 29, 2026. Let's record an event on this watch to keep it open and log the extension. Wait, let's check the watch `Dianthus CAPTIVATE Part B top-line guidance in CIDP` or `Dianthus MoMeNtum Phase 2 top-line data in MMN`. These are Q4 2026. What about `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis`? This is mid-2026 (fire date August 31, 2026). Let's search if there has been any update. Let's check `EMA re-examination outcome on Omeros's narsoplimab in TA-TMA`. Has there been any update on Omeros's narsoplimab re-examination? Let's do a search on Omeros narsoplimab to see if there is any new development. I will state my intent first. I will search for any recent updates (from the last month or so) regarding Omeros and narsoplimab's EMA re-examination or CHMP opinion.

Ah! The negative CHMP opinion was adopted on June 26, 2026. This was already reported in our prior finding: `Omeros's Narsoplimab (Yartemlea) Receives Negative CHMP Opinion for TA-TMA, Spurring Re-examination Request` (slug: `omeros-narsoplimab-chmp-negative-opinion-ta-tma`). So there are no new developments since then (the re-examination process takes several months). Let's check `MoonLake Phase 3 IZAR-1 trial readout of sonelokimab in psoriatic arthritis`. Is there any recent news on this? I will state my intent first. I will search for "MoonLake sonelokimab IZAR-1 Phase 3" or related terms to see if there is any update on this psoriatic arthritis trial.

Ah, the primary endpoint readout for IZAR-1 in PsA is expected in "mid 2026" (which is around now or in the next few weeks / July-August). So no readout has happened yet, but we'll continue to watch it. Let's check `Amgen Tavneos FDA hearing submission and public docket close` watch. Wait, let's record the event on the Tavneos watch. The watch is `Amgen Tavneos FDA hearing submission and public docket close` (id: `019ec855-5381-7936-a3b6-a40d207e679d`). Let's see what the current status is. The FDA has extended the hearing submission deadline to **July 29, 2026** (originally June 29). On Monday, June 29, 2026, the NEJM retracted the pivotal 2021 clinical trial paper for Tavneos due to the FDA's findings of data manipulation and unblinding. So let's record this event on `019ec855-5381-7936-a3b6-a40d207e679d` with `resolves: false` (since the hearing submission is now due July 29, 2026, so the watch is still ongoing or needs to wait until that date). Let's call `record_event`. I will state my intent first. I will record an event for the Amgen Tavneos watch, noting the June 29 retraction of the pivotal trial paper by the NEJM and the extension of the FDA hearing submission deadline to July 29, 2026. This keeps the watch open for the final submission next month.

Ah! The search budget is spent. That is perfectly fine, since we already have outstanding, detailed data for three major findings: 1. The FDA's proposed **Expedited-IND Pilot Program** under **Operation Trailblazer** (updating `hhs-clinical-trials-reform-operation-trailblazer`). 2. Definium Therapeutics' landmark Phase 3 **Emerge trial** success of its LSD-based **DT120 ODT** in major depressive disorder (MDD) (new finding). 3. AbbVie/Genmab's Phase 3 **EPCORE DLBCL-4** trial success of **Epcoritamab plus lenalidomide** in relapsed/refractory DLBCL (new finding). 4. Sobi receiving a Complete Response Letter (CRL) from the FDA for **NASP** (nanoencapsulated sirolimus plus pegadricase) in uncontrolled gout due to third-party manufacturing deficiencies (new finding). Let's carefully write these notes! First, let's update `hhs-clinical-trials-reform-operation-trailblazer`. Let's see: the original note is `hhs-clinical-trials-reform-operation-trailblazer`. Let's write the updated body for this note. Wait, let's review the guidelines for writing notes: - Body shape: # <Title for this finding> <what's happening, told through the specifics — the real quote(s) and the real link(s), not abstract commentary about them> ## Sources - [Story / article title](https://url) — one-line gloss - No YAML frontmatter. - Use wikilinks to link other findings if needed. - Ground it in concrete evidence with 1-2 verbatim quotes. Let's draft the updated `hhs-clinical-trials-reform-operation-trailblazer` note. I will state my intent first. I will write the updated note for the HHS and FDA clinical trials reform ("Operation Trailblazer"), integrating the newly announced Expedited-IND Pilot Program proposal from June 24, 2026.

Now I will write a new note for Definium Therapeutics' Phase 3 success with its LSD-based drug DT120 ODT in major depressive disorder. Let's see: the slug should be `definium-dt120-lsd-depression-phase-3-success`. Let's review the details: - Date: June 22, 2026. - Trial: Emerge trial (NCT06941844), 149-patient Phase 3 study. - Drug: DT120 ODT (orally disintegrating tablet), a proprietary formulation of lysergide (LSD). - Indication: Major Depressive Disorder (MDD). - Primary endpoint: Placebo-adjusted MADRS score reduction of 8.1 points at 6 weeks (p-value highly significant). - Secondary endpoint: Placebo-adjusted MADRS reduction of 7.1 points at 12 weeks. - Safety: No new safety signals, no increased suicidal ideation. - Context: Rebranded from MindMed in January 2026. Executive order by President Trump in April 2026 fast-tracking psychedelics via priority review vouchers, though Definium is navigating a path that avoids political flavor. Let's write this note. I will state my intent first. I will write a new note for Definium Therapeutics' Phase 3 Emerge trial success for its LSD-based formulation DT120 ODT in major depressive disorder, including key statistical outcomes and political context.

Now I will write a new note for Genmab/AbbVie's Phase 3 success with Epcoritamab plus lenalidomide in relapsed/refractory DLBCL. Let's see: the slug should be `genmab-abbvie-epcoritamab-dlbcl-phase-3-success`. Let's review the details: - Date: June 29, 2026. - Trial: Phase 3 EPCORE DLBCL-4 trial (NCT06508658). - Drug: Epcoritamab (EPKINLY/TEPKINLY), a subcutaneous CD3xCD20 bispecific antibody, in combination with oral lenalidomide (Revlimid). - Indication: Relapsed or refractory diffuse large B-cell lymphoma (DLBCL). - Control arm: Standard chemoimmunotherapy (R-GemOx) in patients with at least one prior line of therapy. - Primary endpoint: Statistically significant and clinically meaningful improvement in progression-free survival (PFS). - Efficacy: Risk of disease progression or death was reduced by 60% (US censoring rules, HR 0.40; p-value <0.0001) or 56% (outside US, HR 0.44; p-value <0.0001). - Clinical significance: Represents a highly effective chemotherapy-free regimen in the second-line setting. Let's write this note. I will state my intent first. I will write a new note for Genmab and AbbVie's Phase 3 EPCORE DLBCL-4 trial success, which demonstrated that a chemotherapy-free combination of epcoritamab and lenalidomide significantly improves progression-free survival in relapsed/refractory DLBCL.

Now I will write a new note for Sobi's Complete Response Letter (CRL) from the FDA for NASP in uncontrolled gout. Let's see: the slug should be `sobi-nasp-gout-fda-crl-manufacturing`. Let's review the details: - Date: June 26, 2026. - Drug: NASP (nanoencapsulated sirolimus plus pegadricase), an investigational sequential infusion therapy. - Indication: Uncontrolled gout in adults. - Action: FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA). - Reasons: Chemistry, manufacturing, and controls (CMC) issues, specifically the manufacturing control strategy of the biological component, and contract manufacturing facility deficiencies. - Crucially, the FDA identified **no clinical safety or efficacy concerns** that impact approvability. - Competitive context: Sobi's NASP was designed as a direct challenger to Amgen's blockbuster gout treatment, Krystexxa. It utilizes tolerogenic nanoencapsulated sirolimus (NAS) to prevent the development of anti-drug antibodies (ADAs) against the pegadricase (uricase) component, which is a major limitation of current therapies. Let's write this note. I will state my intent first. I will write a new note detailing the FDA's Complete Response Letter (CRL) to Sobi regarding its BLA for NASP in uncontrolled gout, focusing on the manufacturing deficiencies and competitive positioning.

Now let's check the watches to see if we need to register any new ones or resolve any other threads. Let's see: we have recorded an event on the Tavneos watch `019ec855-5381-7936-a3b6-a40d207e679d` (resolves: false, since the submission deadline was extended to July 29, 2026). Are there any other watches we should register? We should register a watch for Sobi's resubmission of NASP for uncontrolled gout following their meeting with the FDA and resolution of contract manufacturing facility issues. This is a forward-looking catalyst. Let's register this watch. I will state my intent first. I will register a new watch to monitor Sobi's planned resubmission of the BLA for NASP in uncontrolled gout, following the resolution of CMC and contract manufacturing deficiencies.

Excellent. Let's register another watch for the FDA's decision on the proposed Expedited-IND Pilot Program following the close of the public RFI comment period on July 22, 2026. This is a highly significant regulatory policy milestone. I will state my intent first. I will register a watch to monitor the FDA's next steps and potential finalization of the Expedited-IND Pilot Program under Operation Trailblazer, following the close of the public comment period on July 22, 2026.

Great. Are there any other watches? Let's see: we have registered a watch for Sobi's BLA resubmission and the FDA's finalization of the Expedited-IND Pilot Program. What about Definium's other Phase 3 readouts in Generalized Anxiety Disorder (GAD) and low-dose depression? Yes, the Fierce Biotech article mentioned: "Definium is also pitting DT120 against generalized anxiety disorder in two phase 3 trials, alongside a lower-dose phase 3 study in depression. Readouts from these trials are expected later this year..." Let's register a watch for these Phase 3 readouts. I will state my intent first. I will register a watch to monitor Definium's upcoming Phase 3 readouts for DT120 in generalized anxiety disorder (GAD) and low-dose depression, expected by the end of 2026.

Excellent. Now that I have: 1. Updated the existing note on clinical trial reforms (`hhs-clinical-trials-reform-operation-trailblazer`). 2. Created a new note for Definium's Phase 3 success in MDD (`definium-dt120-lsd-depression-phase-3-success`). 3. Created a new note for Genmab/AbbVie's epcoritamab DLBCL success (`genmab-abbvie-epcoritamab-dlbcl-phase-3-success`). 4. Created a new note for Sobi's gout drug CRL (`sobi-nasp-gout-fda-crl-manufacturing`). 5. Recorded an event on the Tavneos watch (`019ec855-5381-7936-a3b6-a40d207e679d`) noting the NEJM retraction and extension of the FDA hearing deadline. 6. Registered three new forward-looking watches. I have completed all the tasks for this research cycle. I will now call `finish_cycle`. I will state my intent first. I will call the `finish_cycle` tool to conclude this research cycle, having successfully processed all key updates and findings.

I have successfully completed this research cycle on topic `019e92c9-9dac-7a47-a1f2-f8f4037c94f9`. Below is a summary of the findings and updates recorded during this cycle. ### Summary of Research Findings 1. **HHS and FDA Clinical Trials Reform: "Operation Trailblazer" and the Proposed Expedited-IND Pilot Program** - **Update to:** `[[hhs-clinical-trials-reform-operation-trailblazer]]` - **What's New:** Following the June 22, 2026 launch of "Operation Trailblazer" by HHS and the FDA, the FDA published a Request for Information (RFI) on June 24, 2026, proposing the **Expedited-IND Pilot Program**. - **Details:** The pilot is designed to accelerate Phase 1 first-in-human (FIH) trial start-up times in the U.S. by 6 to 12 months, attempting to reverse the trend of early-stage clinical research shifting to China. It proposes a network of **"Qualified Research Institutions" (QRIs)** to pre-screen IND components and make rolling recommendations to sponsors and the FDA. The public comment period runs through July 22, 2026. 2. **Definium's LSD-Based DT120 ODT Delivers Landmark Phase 3 Victory in Major Depressive Disorder** - **New Finding:** `[[definium-dt120-lsd-depression-phase-3-success]]` - **Details:** On June 22, 2026, Definium Therapeutics (formerly MindMed) announced highly positive topline results from its Phase 3 **Emerge trial** (NCT06941844) evaluating **DT120 ODT** (a proprietary formulation of lysergide/LSD) in Major Depressive Disorder (MDD). - **Data:** A single 100µg dose achieved a highly significant **8.1-point placebo-adjusted reduction** in MADRS score at 6 weeks (primary endpoint) and a durable **7.1-point reduction** at 12 weeks. The trial omitted active psychological interventions to isolate the drug's biological effect. Definium's leadership highlighted their desire to keep the drug's regulatory path scientific and free from "political flavor" despite recent executive branch focus on fast-tracking psychedelics. 3. **Genmab and AbbVie's Chemotherapy-Free Epcoritamab Combination Achieves Major Phase 3 Win in R/R DLBCL** - **New Finding:** `[[genmab-abbvie-epcoritamab-dlbcl-phase-3-success]]` - **Details:** On June 29, 2026, Genmab and AbbVie announced that the Phase 3 **EPCORE DLBCL-4** trial (NCT06508658) met its primary endpoint. The trial evaluated a chemotherapy-free regimen of subcutaneous epcoritamab (EPKINLY/TEPKINLY) combined with oral lenalidomide against standard chemoimmunotherapy (R-GemOx) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). - **Data:** The combination achieved a **60% risk reduction in disease progression or death** under U.S. censoring rules (HR 0.40, p-value <0.0001) and a 56% reduction under non-U.S. rules (HR 0.44). This represents a highly effective chemotherapy-free alternative in the second-line setting. 4. **FDA Issues Complete Response Letter to Sobi for Gout Therapy NASP Over Manufacturing Deficiencies** - **New Finding:** `[[sobi-nasp-gout-fda-crl-manufacturing]]` - **Details:** On June 26, 2026, Sobi received a Complete Response Letter (CRL) from the FDA regarding its BLA for **NASP** (nanoencapsulated sirolimus plus pegadricase) for uncontrolled gout. - **Deficiencies:** The FDA's decision was strictly focused on chemistry, manufacturing, and controls (CMC) issues, specifically the manufacturing control strategy of the biological component and deficiencies at contract manufacturing facilities. Crucially, the FDA raised **no clinical safety or efficacy concerns**. Sobi is working with its partners to address these issues and plans to request an FDA meeting to map out a path to resubmission. ### Active Watch Updates & Newly Registered Catalysts * **Amgen Tavneos FDA Hearing & Retraction Event:** Filed a tracking event on watch `019ec855-5381-7936-a3b6-a40d207e679d`. On June 29, 2026, the *New England Journal of Medicine* (NEJM) retracted the pivotal 2021 clinical trial paper supporting Tavneos' approval due to the FDA's findings of data manipulation and unblinding. Amgen's deadline to submit its independent DCRI re-adjudication data to the FDA has been extended to **July 29, 2026**, so the watch remains open to track that submission. * **New Watch - Sobi BLA Resubmission:** Registered a watch (`019f1ab8-b786-7130-9ce1-ccf00ee61d03`) to monitor Sobi's formal resubmission of the NASP BLA in uncontrolled gout once CMC and contract manufacturing facility deficiencies are resolved. * **New Watch - FDA Launch of Expedited-IND Pilot:** Registered a watch (`019f1ab8-f9db-7f35-b537-f4db6a56efeb`) to monitor the FDA's finalization, rollout, or designation of the first batch of Qualified Research Institutions (QRIs) under Operation Trailblazer, following the close of the public RFI comment period on July 22, 2026. * **New Watch - Definium GAD and Low-Dose MDD Readouts:** Registered a watch (`019f1ab9-37ce-758f-a72b-8d16fad8f514`) to monitor Definium's other Phase 3 readouts for DT120 in generalized anxiety disorder (two trials) and low-dose depression, expected by the end of 2026.